{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:28:47Z","timestamp":1793460527921,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41581-024-00918-x","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T13:46:18Z","timestamp":1736257578000},"page":"264-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Diuretics in patients with chronic kidney disease"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-6327","authenticated-orcid":false,"given":"Ashish","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-2096","authenticated-orcid":false,"given":"Panagiotis I.","family":"Georgianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"918_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacc.2019.11.055","volume":"75","author":"FJ He","year":"2020","unstructured":"He, F. J., Tan, M., Ma, Y. & MacGregor, G. A. Salt reduction to prevent hypertension and cardiovascular disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 632\u2013647 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"918_CR2","doi-asserted-by":"publisher","first-page":"H203","DOI":"10.1152\/ajpheart.01237.2003","volume":"287","author":"J Titze","year":"2004","unstructured":"Titze, J. et al. Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin. Am. J. Physiol. Heart Circ. Physiol. 287, H203\u2013H208 (2004).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"918_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17820-2","volume":"11","author":"G Rossitto","year":"2020","unstructured":"Rossitto, G. et al. Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nat. Commun. 11, 4222 (2020).","journal-title":"Nat. Commun."},{"key":"918_CR4","doi-asserted-by":"publisher","first-page":"R945","DOI":"10.1152\/ajpregu.00363.2017","volume":"315","author":"P Bie","year":"2018","unstructured":"Bie, P. Mechanisms of sodium balance: total body sodium, surrogate variables, and renal sodium excretion. Am. J. Physiol. Regul. Integr. Comp. Physiol. 315, R945\u2013R962 (2018).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"918_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1161\/01.HYP.7.5.714","volume":"7","author":"HA Koomans","year":"1985","unstructured":"Koomans, H. A., Roos, J. C., Dorhout Mees, E. J. & Delawi, I. M. Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake. Hypertension 7, 714\u2013721 (1985).","journal-title":"Hypertension"},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1136\/bmj.312.7041.1249","volume":"312","author":"P Elliott","year":"1996","unstructured":"Elliott, P. et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 312, 1249\u20131253 (1996).","journal-title":"BMJ"},{"key":"918_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/HYPERTENSIONAHA.123.17959","volume":"81","author":"MA Bailey","year":"2024","unstructured":"Bailey, M. A. & Dhaun, N. Salt sensitivity: causes, consequences, and recent advances. Hypertension 81, 476\u2013489 (2024).","journal-title":"Hypertension"},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMra011078","volume":"346","author":"RJ Johnson","year":"2002","unstructured":"Johnson, R. J., Herrera-Acosta, J., Schreiner, G. F. & Rodriguez-Iturbe, B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N. Engl. J. Med. 346, 913\u2013923 (2002).","journal-title":"N. Engl. J. Med."},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/01.HYP.19.5.464","volume":"19","author":"RJ Johnson","year":"1992","unstructured":"Johnson, R. J. et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 19, 464\u2013474 (1992).","journal-title":"Hypertension"},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1161\/01.HYP.34.1.151","volume":"34","author":"RJ Johnson","year":"1999","unstructured":"Johnson, R. J. et al. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 34, 151\u2013159 (1999).","journal-title":"Hypertension"},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1749-6632.1958.tb46769.x","volume":"71","author":"GE Schreiner","year":"1958","unstructured":"Schreiner, G. E. Chlorothiazide in renal disease. Ann. N. Y. Acad. Sci. 71, 420\u2013429 (1958).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1161\/01.CIR.23.2.200","volume":"23","author":"FC Reubi","year":"1961","unstructured":"Reubi, F. C. & Cottier, P. T. Effects of reduced glomerular filtration rate on responsiveness to chlorothiazide and mercurial diuretics. Circulation 23, 200\u2013210 (1961).","journal-title":"Circulation"},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/bmj.4.5834.196","volume":"4","author":"HJ Dargie","year":"1972","unstructured":"Dargie, H. J., Allison, M. E., Kennedy, A. C. & Gray, M. J. High dosage metolazone in chronic renal failure. Br. Med. J. 4, 196\u2013198 (1972).","journal-title":"Br. Med. J."},{"key":"918_CR14","first-page":"157","volume":"2","author":"HJ Dargie","year":"1974","unstructured":"Dargie, H. J., Allison, M. E., Kennedy, A. C. & Gray, M. J. Efficacy of metolazone in patients with renal edema. Clin. Nephrol. 2, 157\u2013160 (1974).","journal-title":"Clin. Nephrol."},{"key":"918_CR15","first-page":"357","volume":"13","author":"WM Bennett","year":"1973","unstructured":"Bennett, W. M. & Porter, G. A. Efficacy and safety of metolazone in renal failure and the nephrotic syndrome. J. Clin. Pharmacol. 13, 357\u2013364 (1973).","journal-title":"J. Clin. Pharmacol."},{"key":"918_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000180257","volume":"12","author":"PW Craswell","year":"1974","unstructured":"Craswell, P. W., Ezzat, E., Kopstein, J., Varghese, Z. & Moorhead, J. F. Use of metolazone, a new diuretic, in patients with renal disease. Nephron 12, 63\u201373 (1974).","journal-title":"Nephron"},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/009127007701700409","volume":"17","author":"RR Paton","year":"1977","unstructured":"Paton, R. R. & Kane, R. E. Long-term diuretic therapy with metolazone of renal failure and the nephrotic syndrome. J. Clin. Pharmacol. 17, 243\u2013251 (1977).","journal-title":"J. Clin. Pharmacol."},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0002-9343(82)90854-3","volume":"72","author":"GL Wollam","year":"1982","unstructured":"Wollam, G. L., Tarazi, R. C., Bravo, E. L. & Dustan, H. P. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am. J. Med. 72, 929\u2013938 (1982).","journal-title":"Am. J. Med."},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/ki.1994.298","volume":"46","author":"D Fliser","year":"1994","unstructured":"Fliser, D., Schroter, M., Nerubeck, M. & Ritz, E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 46, 482\u2013488 (1994).","journal-title":"Kidney Int."},{"key":"918_CR20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00005344-199509000-00008","volume":"26","author":"H Knauf","year":"1995","unstructured":"Knauf, H. & Mutschler, E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J. Cardiovasc. Pharmacol. 26, 394\u2013400 (1995).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ndt\/gfh650","volume":"20","author":"B Dussol","year":"2005","unstructured":"Dussol, B. et al. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol. Dial. Transpl. 20, 349\u2013353 (2005).","journal-title":"Nephrol. Dial. Transpl."},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1751-7176.2011.00564.x","volume":"14","author":"B Dussol","year":"2012","unstructured":"Dussol, B. et al. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J. Clin. Hypertens. 14, 32\u201337 (2012).","journal-title":"J. Clin. Hypertens."},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton, P. K. et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 71, 1269\u20131324 (2018).","journal-title":"Hypertension"},{"key":"918_CR24","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104 (2018).","journal-title":"Eur. Heart J."},{"key":"918_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"Unger, T. et al. 2020 International Society of Hypertension global hypertension practice guidelines. J. Hypertens. 38, 982\u20131004 (2020).","journal-title":"J. Hypertens."},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jash.2012.07.004","volume":"6","author":"R Agarwal","year":"2012","unstructured":"Agarwal, R. & Sinha, A. D. Thiazide diuretics in advanced chronic kidney disease. J. Am. Soc. Hypertens. 6, 299\u2013308 (2012).","journal-title":"J. Am. Soc. Hypertens."},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000358603","volume":"39","author":"R Agarwal","year":"2014","unstructured":"Agarwal, R., Sinha, A. D., Pappas, M. K. & Ammous, F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am. J. Nephrol. 39, 171\u2013182 (2014).","journal-title":"Am. J. Nephrol."},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1159\/000508700","volume":"51","author":"R Agarwal","year":"2020","unstructured":"Agarwal, R. et al. Design and baseline characteristics of the chlorthalidone in chronic kidney disease (CLICK) Trial. Am. J. Nephrol. 51, 542\u2013552 (2020).","journal-title":"Am. J. Nephrol."},{"key":"918_CR29","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal, R. et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N. Engl. J. Med. 385, 2507\u20132519 (2021).","journal-title":"N. Engl. J. Med."},{"key":"918_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/ndt\/gfab328","volume":"37","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. Spironolactone and chlorthalidone-old drugs, new uses-but approach with caution. Nephrol. Dial. Transpl. 37, 407\u2013408 (2022).","journal-title":"Nephrol. Dial. Transpl."},{"key":"918_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41586-023-05718-0","volume":"614","author":"M Fan","year":"2023","unstructured":"Fan, M., Zhang, J., Lee, C. L., Zhang, J. & Feng, L. Structure and thiazide inhibition mechanism of the human Na-Cl cotransporter. Nature 614, 788\u2013793 (2023).","journal-title":"Nature"},{"key":"918_CR32","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI40145","volume":"120","author":"F Leviel","year":"2010","unstructured":"Leviel, F. et al. The Na+-dependent chloride-bicarbonate exchanger SLC4A8 mediates an electroneutral Na+ reabsorption process in the renal cortical collecting ducts of mice. J. Clin. Invest. 120, 1627\u20131635 (2010).","journal-title":"J. Clin. Invest."},{"key":"918_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/0014-5793(75)80012-3","volume":"53","author":"N Delihas","year":"1975","unstructured":"Delihas, N., Topol, E. & Larrinua, I. Changes in accessibility to chemical modification of Escherichia coli ribosomes induced by streptomycin. FEBS Lett. 53, 170\u2013175 (1975).","journal-title":"FEBS Lett."},{"key":"918_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/01.CIR.42.3.479","volume":"42","author":"A Leth","year":"1970","unstructured":"Leth, A. Changes in plasma and extracellular fluid volumes in patients with essential hypertension during long-term treatment with hydrochlorothiazide. Circulation 42, 479\u2013485 (1970).","journal-title":"Circulation"},{"key":"918_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.0954-6820.1980.tb09718.x","volume":"207","author":"P van Brummelen","year":"1980","unstructured":"van Brummelen, P. & Schalekamp, M. A. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. Acta Med. Scand. 207, 259\u2013264 (1980).","journal-title":"Acta Med. Scand."},{"key":"918_CR36","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJM196006232622502","volume":"262","author":"ED Frohlich","year":"1960","unstructured":"Frohlich, E. D., Schnaper, H. W., Wilson, I. M. & Freis, E. D. Hemodynamic alterations in hypertensive patients due to chlorothiazide. N. Engl. J. Med. 262, 1261\u20131263 (1960).","journal-title":"N. Engl. J. Med."},{"key":"918_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.21.1.21","volume":"21","author":"J Conway","year":"1960","unstructured":"Conway, J. & Lauwers, P. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 21, 21\u201327 (1960).","journal-title":"Circulation"},{"key":"918_CR38","first-page":"403","volume":"56","author":"P Lauwers","year":"1960","unstructured":"Lauwers, P. & Conway, J. Effect of long-term treatment with chlorothiazide on body fluids, serum electrolytes, and exchangeable sodium in hypertensive patients. J. Lab. Clin. Med. 56, 403\u2013408 (1960).","journal-title":"J. Lab. Clin. Med."},{"key":"918_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.1980.44","volume":"27","author":"P van Brummelen","year":"1980","unstructured":"van Brummelen, P., Man in \u2018t Veld, A. J. & Schalekamp, M. A. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin. Pharmacol. Ther. 27, 328\u2013336 (1980).","journal-title":"Clin. Pharmacol. Ther."},{"key":"918_CR40","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/01.CIR.24.4.788","volume":"24","author":"BM Winer","year":"1961","unstructured":"Winer, B. M. The antihypertensive mechanisms of salt depletion induced by hydrochlorothiazide. Circulation 24, 788\u2013796 (1961).","journal-title":"Circulation"},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/01.HYP.12.3.244","volume":"12","author":"ED Freis","year":"1988","unstructured":"Freis, E. D., Reda, D. J. & Materson, B. J. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension 12, 244\u2013250 (1988).","journal-title":"Hypertension"},{"key":"918_CR42","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ki.1983.22","volume":"23","author":"P Weidmann","year":"1983","unstructured":"Weidmann, P. et al. Antihypertensive mechanism of diuretic treatment with chlorthalidone. Complementary roles of sympathetic axis and sodium. Kidney Int. 23, 320\u2013326 (1983).","journal-title":"Kidney Int."},{"key":"918_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/01.RES.42.3.376","volume":"42","author":"ED Vaughan Jr","year":"1978","unstructured":"Vaughan, E. D. Jr, Carey, R. M., Peach, M. J., Ackerly, J. A. & Ayers, C. R. The renin response to diuretic therapy: a limitation of antihypertensive potential. Circ. Res. 42, 376\u2013381 (1978).","journal-title":"Circ. Res."},{"key":"918_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/01.HYP.3.4.441","volume":"3","author":"H Gavras","year":"1981","unstructured":"Gavras, H. et al. Role of reactive hyperreninemia in blood pressure changes induced by sodium depletion in patients with refractory hypertension. Hypertension 3, 441\u2013447 (1981).","journal-title":"Hypertension"},{"key":"918_CR45","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2215\/CJN.0000000000000484","volume":"19","author":"R Agarwal","year":"2024","unstructured":"Agarwal, R., Sinha, A. D. & Tu, W. Mechanisms of antihypertensive effect of chlorthalidone in advanced chronic kidney disease: a causal mediation analysis. Clin. J. Am. Soc. Nephrol. 19, 1025\u20131032 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"918_CR46","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1681\/ASN.2019090905","volume":"31","author":"DM Bovee","year":"2020","unstructured":"Bovee, D. M. et al. A randomized trial of distal diuretics versus dietary sodium restriction for hypertension in chronic kidney disease. J. Am. Soc. Nephrol. 31, 650\u2013662 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"918_CR47","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI24134","volume":"115","author":"T Nijenhuis","year":"2005","unstructured":"Nijenhuis, T. et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J. Clin. Invest. 115, 1651\u20131658 (2005).","journal-title":"J. Clin. Invest."},{"key":"918_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/ckj\/sfac272","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal, R. Should we CLICK on chlorthalidone for treatment-resistant hypertension in chronic kidney disease? Clin. Kidney J. 16, 793\u2013796 (2023).","journal-title":"Clin. Kidney J."},{"key":"918_CR49","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1001\/archinte.1990.00390170061014","volume":"150","author":"MS Kochar","year":"1990","unstructured":"Kochar, M. S., Landry, K. M. & Ristow, S. M. Effects of reduction in dose and discontinuation of hydrochlorothiazide in patients with controlled essential hypertension. Arch. Intern. Med. 150, 1009\u20131011 (1990).","journal-title":"Arch. Intern. Med."},{"key":"918_CR50","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/bmj.300.6730.975","volume":"300","author":"JE Carlsen","year":"1990","unstructured":"Carlsen, J. E., Kober, L., Torp-Pedersen, C. & Johansen, P. Relation between dose of bendroflumethiazide, antihypertensive effect, and adverse biochemical effects. Br. Med. J. 300, 975\u2013978 (1990).","journal-title":"Br. Med. J."},{"key":"918_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00003495-199549010-00009","volume":"49","author":"CJ Dunn","year":"1995","unstructured":"Dunn, C. J., Fitton, A. & Brogden, R. N. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 49, 121\u2013142 (1995).","journal-title":"Drugs"},{"key":"918_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ki.1982.134","volume":"22","author":"S Kaojarern","year":"1982","unstructured":"Kaojarern, S., Day, B. & Brater, D. C. The time course of delivery of furosemide into urine is an independent determinant of overall response. Kidney Int. 22, 69\u201374 (1982).","journal-title":"Kidney Int."},{"key":"918_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/clpt.1994.98","volume":"56","author":"TWB Gehr","year":"1994","unstructured":"Gehr, T. W. B. et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 56, 31\u201338 (1994).","journal-title":"Clin. Pharmacol. Ther."},{"key":"918_CR54","first-page":"73","volume":"36","author":"Anonymous.","year":"1994","unstructured":"Anonymous. Torsemide (Demadex) \u2014 a new loop diuretic. Med. Lett. Drugs Ther. 36, 73\u201374 (1994).","journal-title":"Med. Lett. Drugs Ther."},{"key":"918_CR55","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1046\/j.1523-1755.2003.00273.x","volume":"64","author":"N Vasavada","year":"2003","unstructured":"Vasavada, N. & Agarwal, R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 64, 1772\u20131779 (2003).","journal-title":"Kidney Int."},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/00005344-199322003-00005","volume":"22","author":"FC Luft","year":"1993","unstructured":"Luft, F. C. Torasemide in the treatment of arterial hypertension. J. Cardiovasc. Pharmacol. 22, S32\u2013S39 (1993).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"918_CR57","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/106002809502900411","volume":"29","author":"JS Blose","year":"1995","unstructured":"Blose, J. S., Adams, K. F. J. & Patterson, J. H. Torsemide: a pyridine-sulfonylurea loop diuretic. Ann. Pharmacother. 29, 396\u2013402 (1995).","journal-title":"Ann. Pharmacother."},{"key":"918_CR58","first-page":"S69","volume":"38","author":"D Russo","year":"1992","unstructured":"Russo, D., Memoli, B. & Andreucci, A. E. The place of loop diuretics in the treatment of acute and chronic renal failure. Clin. Nephrol. 38, S69\u2013S73 (1992).","journal-title":"Clin. Nephrol."},{"key":"918_CR59","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/00005344-199322003-00004","volume":"22","author":"DC Brater","year":"1993","unstructured":"Brater, D. C. Pharmacokinetics and pharmacodynamics of torasemide in health and disease. J. Cardiovasc. Pharmacol. 22, S24\u2013S31 (1993).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"918_CR60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/eurheartj\/13.suppl_G.96","volume":"13","author":"BN Prichard","year":"1992","unstructured":"Prichard, B. N., Owens, C. W. & Woolf, A. S. Adverse reactions to diuretics. Eur. Heart J. 13, 96\u2013103 (1992).","journal-title":"Eur. Heart J."},{"key":"918_CR61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"918_CR62","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger, M. H., Roniker, B., Krause, S. L. & Weiss, R. J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15, 709\u2013716 (2002).","journal-title":"Am. J. Hypertens."},{"key":"918_CR63","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen, B. L. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation 145, 1460\u20131470 (2022).","journal-title":"Circulation"},{"key":"918_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","volume":"44","author":"S Ito","year":"2021","unstructured":"Ito, S., Itoh, H., Rakugi, H., Okuda, Y. & Iijima, S. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction. Hypertens. Res. 44, 489\u2013497 (2021).","journal-title":"Hypertens. Res."},{"key":"918_CR65","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","volume":"143","author":"N Ye","year":"2021","unstructured":"Ye, N. et al. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation 143, 1735\u20131749 (2021).","journal-title":"Circulation"},{"key":"918_CR66","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"DA Calhoun","year":"2008","unstructured":"Calhoun, D. A. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51, 1403\u20131419 (2008).","journal-title":"Hypertension"},{"key":"918_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap, J. J. et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart 105, 98\u2013105 (2019).","journal-title":"Heart"},{"key":"918_CR68","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(15)00418-3","volume":"386","author":"P Rossignol","year":"2015","unstructured":"Rossignol, P. et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet 386, 1588\u20131598 (2015).","journal-title":"Lancet"},{"key":"918_CR69","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.jacc.2012.12.061","volume":"61","author":"L De Nicola","year":"2013","unstructured":"De Nicola, L. et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J. Am. Coll. Cardiol. 61, 2461\u20132467 (2013). (In English).","journal-title":"J. Am. Coll. Cardiol."},{"key":"918_CR70","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015).","journal-title":"Lancet"},{"key":"918_CR71","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","volume":"99","author":"AK Cheung","year":"2021","unstructured":"Cheung, A. K. et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 99, 559\u2013569 (2021).","journal-title":"Kidney Int."},{"key":"918_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","volume":"7","author":"IE Beldhuis","year":"2019","unstructured":"Beldhuis, I. E. et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. JACC Heart Fail. 7, 25\u201332 (2019).","journal-title":"JACC Heart Fail."},{"key":"918_CR73","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","volume":"78","author":"RB Patel","year":"2021","unstructured":"Patel, R. B. et al. Kidney function and outcomes in patients hospitalized with heart failure. J. Am. Coll. Cardiol. 78, 330\u2013343 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"918_CR74","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal, R. et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394, 1540\u20131550 (2019).","journal-title":"Lancet"},{"key":"918_CR75","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"918_CR76","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2023","unstructured":"Agarwal, R. et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin. Kidney J. 16, 293\u2013302 (2023).","journal-title":"Clin. Kidney J."},{"key":"918_CR77","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","volume":"78","author":"G Bakris","year":"2021","unstructured":"Bakris, G. et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD Study. Hypertension 78, 74\u201381 (2021).","journal-title":"Hypertension"},{"key":"918_CR78","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/HYPERTENSIONAHA.120.15199","volume":"76","author":"G Bakris","year":"2020","unstructured":"Bakris, G., Yang, Y. F. & Pitt, B. Mineralocorticoid receptor antagonists for hypertension management in advanced chronic kidney disease: BLOCK-CKD trial. Hypertension 76, 144\u2013149 (2020).","journal-title":"Hypertension"},{"key":"918_CR79","unstructured":"Novo Nordisk Global. novonordisk.com https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=168529 (2024)."},{"key":"918_CR80","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/CIRCULATIONAHA.122.060167","volume":"146","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R., Sinha, A. D. & Tu, W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease. Circulation 146, 718\u2013720 (2022).","journal-title":"Circulation"},{"key":"918_CR81","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1161\/CIRCULATIONAHA.122.061029","volume":"146","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. Hydrochlorothiazide versus chlorthalidone: what is the difference? Circulation 146, 1641\u20131643 (2022).","journal-title":"Circulation"},{"key":"918_CR82","doi-asserted-by":"crossref","unstructured":"Sarafidis, P. et al. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension. Nephrol. Dial. Transpl. 39, 929\u2013943 (2024).","DOI":"10.1093\/ndt\/gfae041"},{"key":"918_CR83","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1042\/cs0640153","volume":"64","author":"HA Koomans","year":"1983","unstructured":"Koomans, H. A., Geers, A. B., Boer, P., Roos, J. C. & Dorhout Mees, E. J. A study on the distribution of body fluids after rapid saline expansion in normal subjects and in patients with renal insufficiency: preferential intravascular deposition in renal failure. Clin. Sci. 64, 153\u2013160 (1983).","journal-title":"Clin. Sci."},{"key":"918_CR84","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/clpt.1986.151","volume":"40","author":"DC Brater","year":"1986","unstructured":"Brater, D. C., Anderson, S. A. & Brown-Cartwright, D. Response to furosemide in chronic renal insufficiency: rationale for limited doses. Clin. Pharmacol. Ther. 40, 134\u2013139 (1986).","journal-title":"Clin. Pharmacol. Ther."},{"key":"918_CR85","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker, G. M. et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 364, 797\u2013805 (2011).","journal-title":"N. Engl. J. Med."},{"key":"918_CR86","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","volume":"29","author":"JM Ter Maaten","year":"2023","unstructured":"Ter Maaten, J. M. et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat. Med. 29, 2625\u20132632 (2023).","journal-title":"Nat. Med."},{"key":"918_CR87","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030044","volume":"12","author":"N Oliva-Damaso","year":"2023","unstructured":"Oliva-Damaso, N., Nunez, J. & Soler, M. J. Spot urinary sodium as a biomarker of diuretic response in acute heart failure. J. Am. Heart Assoc. 12, e030044 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"918_CR88","doi-asserted-by":"publisher","first-page":"360","DOI":"10.7326\/0003-4819-115-5-360","volume":"115","author":"DW Rudy","year":"1991","unstructured":"Rudy, D. W., Voelker, J. R., Greene, P. K., Esprza, F. A. & Brater, D. C. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann. Intern. Med. 115, 360\u2013366 (1991).","journal-title":"Ann. Intern. Med."},{"key":"918_CR89","first-page":"333","volume":"8","author":"DC Brater","year":"1988","unstructured":"Brater, D. C. Use of diuretics in chronic renal insufficiency and nephrotic syndrome. Semin. Nephrol. 8, 333\u2013341 (1988).","journal-title":"Semin. Nephrol."},{"key":"918_CR90","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa022963","volume":"349","author":"BL Strom","year":"2003","unstructured":"Strom, B. L. et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N. Engl. J. Med. 349, 1628\u20131635 (2003).","journal-title":"N. Engl. J. Med."},{"key":"918_CR91","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00356178","volume":"6","author":"SE Quaggin","year":"1995","unstructured":"Quaggin, S. E., Payne, J. A., Forbush, B. III & Igarashi, P. Localization of the renal Na-K-Cl cotransporter gene (Slc12a1) on mouse chromosome 2. Mamm. Genome 6, 557\u2013558 (1995).","journal-title":"Mamm. Genome"},{"key":"918_CR92","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/bmj.38902.605347.7C","volume":"333","author":"KM Ho","year":"2006","unstructured":"Ho, K. M. & Sheridan, D. J. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 333, 420 (2006).","journal-title":"BMJ"},{"key":"918_CR93","first-page":"127","volume":"11","author":"LP Rybak","year":"1982","unstructured":"Rybak, L. P. Pathophysiology of furosemide ototoxicity. J. Otolaryngol. 11, 127\u2013133 (1982).","journal-title":"J. Otolaryngol."},{"key":"918_CR94","first-page":"450","volume":"102","author":"CS Wilcox","year":"1983","unstructured":"Wilcox, C. S., Mitch, W. E., Kelly, R. A., Skorecki, K. & Meyer, T. W. Response of the kidney to furosemide. I. Effect of salt intake and renal compensation. J. Lab. Clin. Med. 102, 450\u2013458 (1983).","journal-title":"J. Lab. Clin. Med."},{"key":"918_CR95","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-114-10-886","volume":"114","author":"DH Ellison","year":"1991","unstructured":"Ellison, D. H. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann. Intern. Med. 114, 886\u2013894 (1991).","journal-title":"Ann. Intern. Med."},{"key":"918_CR96","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.ekir.2024.02.1393","volume":"9","author":"N Okuno-Ozeki","year":"2024","unstructured":"Okuno-Ozeki, N. et al. Aversion to a high salt taste is disturbed in patients with CKD. Kidney Int. Rep. 9, 1254\u20131264 (2024).","journal-title":"Kidney Int. Rep."},{"key":"918_CR97","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.2009.214","volume":"76","author":"T Kusaba","year":"2009","unstructured":"Kusaba, T. et al. Sodium restriction improves the gustatory threshold for salty taste in patients with chronic kidney disease. Kidney Int. 76, 638\u2013643 (2009).","journal-title":"Kidney Int."},{"key":"918_CR98","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1136\/bmj.280.6231.1577","volume":"280","author":"BO Odlind","year":"1980","unstructured":"Odlind, B. O. & Beermann, B. Diuretic resistance: reduced bioavailability and effect of oral frusemide. Br. Med. J. 280, 1577 (1980).","journal-title":"Br. Med. J."},{"key":"918_CR99","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ki.1982.149","volume":"22","author":"DC Brater","year":"1982","unstructured":"Brater, D. C. et al. Absorption and disposition of furosemide in congestive heart failure. Kidney Int. 22, 171\u2013176 (1982).","journal-title":"Kidney Int."},{"key":"918_CR100","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/jps.2600690526","volume":"69","author":"DE Smith","year":"1980","unstructured":"Smith, D. E., Gee, W. L., Brater, D. C., Lin, E. T. & Benet, L. Z. Preliminary evaluation of furosemide-probenecid interaction in humans. J. Pharm. Sci. 69, 571\u2013575 (1980).","journal-title":"J. Pharm. Sci."},{"key":"918_CR101","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/jps.2600730821","volume":"73","author":"AA Holazo","year":"1984","unstructured":"Holazo, A. A., Colburn, W. A., Gustafson, J. H., Young, R. L. & Parsonnet, M. Pharmacokinetics of bumetanide following intravenous, intramuscular, and oral administrations to normal subjects. J. Pharm. Sci. 73, 1108\u20131113 (1984).","journal-title":"J. Pharm. Sci."},{"key":"918_CR102","first-page":"160","volume":"38","author":"M Lesne","year":"1988","unstructured":"Lesne, M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittelforschung 38, 160\u2013163 (1988).","journal-title":"Arzneimittelforschung"},{"key":"918_CR103","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cpt1974164659","volume":"16","author":"CM Huang","year":"1974","unstructured":"Huang, C. M., Atkinson, A. J. Jr, Levin, M., Levin, N. W. & Quintanilla, A. Pharmacokinetics of furosemide in advanced renal failure. Clin. Pharmacol. Ther. 16, 659\u2013666 (1974).","journal-title":"Clin. Pharmacol. Ther."},{"key":"918_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF03259733","volume":"6","author":"U Gladziwa","year":"1993","unstructured":"Gladziwa, U. et al. Pharmacokinetics of furosemide in patients with chronic-renal-failure. Drug. Invest. 6, 137\u2013143 (1993).","journal-title":"Drug. Invest."},{"key":"918_CR105","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.1986.112","volume":"39","author":"HS Lau","year":"1986","unstructured":"Lau, H. S., Hyneck, M. L., Berardi, R. R., Swartz, R. D. & Smith, D. E. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure. Clin. Pharmacol. Ther. 39, 635\u2013645 (1986).","journal-title":"Clin. Pharmacol. Ther."},{"key":"918_CR106","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2125.1983.tb01493.x","volume":"15","author":"LA Marcantonio","year":"1983","unstructured":"Marcantonio, L. A. et al. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease. Br. J. Clin. Pharmacol. 15, 245\u2013252 (1983).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"918_CR107","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ki.1987.192","volume":"32","author":"M Inoue","year":"1987","unstructured":"Inoue, M. et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int. 32, 198\u2013203 (1987).","journal-title":"Kidney Int."},{"key":"918_CR108","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0090-9556(24)14887-8","volume":"27","author":"V Pichette","year":"1999","unstructured":"Pichette, V., Geadah, D. & du Souich, P. Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. Drug. Metab. Dispos. 27, 81\u201385 (1999).","journal-title":"Drug. Metab. Dispos."},{"key":"918_CR109","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/0003-4819-113-2-155","volume":"113","author":"RW Schrier","year":"1990","unstructured":"Schrier, R. W. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann. Intern. Med. 113, 155\u2013159 (1990).","journal-title":"Ann. Intern. Med."},{"key":"918_CR110","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0022-3565(25)20166-5","volume":"252","author":"KA Kirchner","year":"1990","unstructured":"Kirchner, K. A., Voelker, J. A. & Brater, D. C. Intratubular albumin blunts the response to furosemide \u2014 a mechanism for diuretic resistance in the nephrotic syndrome. J. Pharmacol. Exp. Ther. 252, 1097\u20131101 (1990).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"918_CR111","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ki.1991.228","volume":"40","author":"KA Kirchner","year":"1991","unstructured":"Kirchner, K. A., Voelker, J. A. & Brater, D. C. Binding inhibitors restore fursemide potency in tubule fluid containing albumin. Kidney Int. 40, 418\u2013424 (1991).","journal-title":"Kidney Int."},{"key":"918_CR112","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1681\/ASN.2008040364","volume":"20","author":"P Svenningsen","year":"2009","unstructured":"Svenningsen, P. et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J. Am. Soc. Nephrol. 20, 299\u2013310 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"918_CR113","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/ndt\/gfu402","volume":"30","author":"H Andersen","year":"2015","unstructured":"Andersen, H. et al. Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells. Nephrol. Dial. Transpl. 30, 781\u2013789 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"918_CR114","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2215\/CJN.12261115","volume":"11","author":"A Schork","year":"2016","unstructured":"Schork, A. et al. Association of plasminuria with overhydration in patients with CKD. Clin. J. Am. Soc. Nephrol. 11, 761\u2013769 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"918_CR115","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2017.07.023","volume":"93","author":"BN Bohnert","year":"2018","unstructured":"Bohnert, B. N. et al. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney Int. 93, 159\u2013172 (2018).","journal-title":"Kidney Int."},{"key":"918_CR116","doi-asserted-by":"crossref","unstructured":"Fila, M. et al. A variant of ASIC2 mediates sodium retention in nephrotic syndrome. JCI Insight 6, e148588 (2021).","DOI":"10.1172\/jci.insight.148588"},{"key":"918_CR117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0022-3565(25)32257-3","volume":"215","author":"P Chennavasin","year":"1980","unstructured":"Chennavasin, P., Seiwell, R. & Brater, D. C. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J. Pharmacol. Exp. Ther. 215, 77\u201381 (1980).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"918_CR118","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/ki.1985.11","volume":"27","author":"DC Brater","year":"1985","unstructured":"Brater, D. C., Anderson, S., Baird, B. & Campbell, W. B. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 27, 66\u201373 (1985).","journal-title":"Kidney Int."},{"key":"918_CR119","doi-asserted-by":"publisher","first-page":"F11","DOI":"10.1152\/ajprenal.00119.2002","volume":"284","author":"SS Shankar","year":"2003","unstructured":"Shankar, S. S. & Brater, D. C. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am. J. Physiol. Renal Physiol. 284, F11\u2013F21 (2003).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"918_CR120","first-page":"F219","volume":"277","author":"P Fernandez-Llama","year":"1999","unstructured":"Fernandez-Llama, P. et al. Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle\u2019s loop. Am. J. Physiol. 277, F219\u2013F226 (1999).","journal-title":"Am. J. Physiol."},{"key":"918_CR121","first-page":"F1269","volume":"24","author":"BA Stanton","year":"1988","unstructured":"Stanton, B. A. & Kaissling, B. Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. Am. J. Physiol. 24, F1269\u2013F1275 (1988).","journal-title":"Am. J. Physiol."},{"key":"918_CR122","first-page":"F1256","volume":"255","author":"B Kaissling","year":"1988","unstructured":"Kaissling, B. & Stanton, B. A. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am. J. Physiol. 255, F1256\u2013F1268 (1988).","journal-title":"Am. J. Physiol."},{"key":"918_CR123","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI81505","volume":"125","author":"MA Knepper","year":"2015","unstructured":"Knepper, M. A. Systems biology of diuretic resistance. J. Clin. Invest. 125, 1793\u20131795 (2015).","journal-title":"J. Clin. Invest."},{"key":"918_CR124","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1172\/JCI78558","volume":"125","author":"PR Grimm","year":"2015","unstructured":"Grimm, P. R. et al. Integrated compensatory network is activated in the absence of NCC phosphorylation. J. Clin. Invest. 125, 2136\u20132150 (2015).","journal-title":"J. Clin. Invest."},{"key":"918_CR125","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1681\/ASN.V1161100","volume":"11","author":"R Agarwal","year":"2000","unstructured":"Agarwal, R., Gorski, J. C., Sundblad, K. & Brater, D. C. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J. Am. Soc. Nephrol. 11, 1100\u20131105 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"918_CR126","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2165\/00003495-198530050-00003","volume":"30","author":"DC Brater","year":"1985","unstructured":"Brater, D. C. Diuretic resistance: why it happens and what to do about it? Drugs 30, 427\u2013443 (1985).","journal-title":"Drugs"},{"key":"918_CR127","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens, W. et al. Acetazolamide in acute decompensated heart failure with volume overload. N. Engl. J. Med. 387, 1185\u20131195 (2022).","journal-title":"N. Engl. J. Med."},{"key":"918_CR128","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1172\/JCI63492","volume":"123","author":"V Gueutin","year":"2013","unstructured":"Gueutin, V. et al. Renal beta-intercalated cells maintain body fluid and electrolyte balance. J. Clin. Invest. 123, 4219\u20134231 (2013).","journal-title":"J. Clin. Invest."},{"key":"918_CR129","doi-asserted-by":"publisher","first-page":"13368","DOI":"10.1073\/pnas.1202671109","volume":"109","author":"M Soleimani","year":"2012","unstructured":"Soleimani, M. et al. Double knockout of pendrin and Na-Cl cotransporter (NCC) causes severe salt wasting, volume depletion, and renal failure. Proc. Natl Acad. Sci. USA 109, 13368\u201313373 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"918_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079327","volume":"8","author":"K Zahedi","year":"2013","unstructured":"Zahedi, K., Barone, S., Xu, J. & Soleimani, M. Potentiation of the effect of thiazide derivatives by carbonic anhydrase inhibitors: molecular mechanisms and potential clinical implications. PLoS ONE 8, e79327 (2013).","journal-title":"PLoS ONE"},{"key":"918_CR131","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jash.2011.02.004","volume":"5","author":"LM Ortega","year":"2011","unstructured":"Ortega, L. M. & Materson, B. J. Hypertension in peritoneal dialysis patients: epidemiology, pathogenesis, and treatment. J. Am. Soc. Hypertens. 5, 128\u2013136 (2011).","journal-title":"J. Am. Soc. Hypertens."},{"key":"918_CR132","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/089686080302300406","volume":"23","author":"RW van Olden","year":"2003","unstructured":"van Olden, R. W., Guchelaar, H. J., Struijk, D. G., Krediet, R. T. & Arisz, L. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit. Dial. Int. 23, 339\u2013347 (2003).","journal-title":"Perit. Dial. Int."},{"key":"918_CR133","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1046\/j.1523-1755.2001.0590031128.x","volume":"59","author":"JF Medcalf","year":"2001","unstructured":"Medcalf, J. F., Harris, K. P. & Walls, J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 59, 1128\u20131133 (2001).","journal-title":"Kidney Int."},{"key":"918_CR134","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2215\/CJN.13361118","volume":"14","author":"K Wang","year":"2019","unstructured":"Wang, K. & Bansal, N. Diuretic use in incident ESKD: are we out of the loop? Clin. J. Am. Soc. Nephrol. 14, 13\u201315 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"918_CR135","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2215\/CJN.05080418","volume":"14","author":"S Sibbel","year":"2019","unstructured":"Sibbel, S. et al. Association of continuation of loop diuretics at hemodialysis initiation with clinical outcomes. Clin. J. Am. Soc. Nephrol. 14, 95\u2013102 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"918_CR136","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.ekir.2022.07.003","volume":"7","author":"JE Flythe","year":"2022","unstructured":"Flythe, J. E. et al. Efficacy, safety, and tolerability of oral furosemide among patients receiving hemodialysis: a pilot study. Kidney Int. Rep. 7, 2186\u20132195 (2022).","journal-title":"Kidney Int. Rep."},{"key":"918_CR137","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/ndt\/gfm805","volume":"23","author":"SY Hayashi","year":"2008","unstructured":"Hayashi, S. Y. et al. Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. Nephrol. Dial. Transpl. 23, 1355\u20131361 (2008).","journal-title":"Nephrol. Dial. Transpl."},{"key":"918_CR138","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","volume":"31","author":"BF Palmer","year":"2011","unstructured":"Palmer, B. F. Metabolic complications associated with use of diuretics. Semin. Nephrol. 31, 542\u2013552 (2011).","journal-title":"Semin. Nephrol."},{"key":"918_CR139","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/1060028016683971","volume":"51","author":"CJ Michaud","year":"2017","unstructured":"Michaud, C. J. & Mintus, K. C. Intravenous chlorothiazide versus enteral metolazone to augment loop diuretic therapy in the intensive care unit. Ann. Pharmacother. 51, 286\u2013292 (2017).","journal-title":"Ann. Pharmacother."},{"key":"918_CR140","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MEJ.0000000000000691","volume":"27","author":"G Lindner","year":"2020","unstructured":"Lindner, G. et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. Eur. J. Emerg. Med. 27, 329\u2013337 (2020).","journal-title":"Eur. J. Emerg. Med."},{"key":"918_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M23-1989","volume":"177","author":"NW Andersson","year":"2024","unstructured":"Andersson, N. W. et al. Cumulative incidence of thiazide-induced hyponatremia: a population-based cohort study. Ann. Intern. Med. 177, 1\u201311 (2024).","journal-title":"Ann. Intern. Med."},{"key":"918_CR142","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jebm.12601","volume":"17","author":"S Kwon","year":"2024","unstructured":"Kwon, S. et al. Thiazide-associated hyponatremia in arterial hypertension patients: a nationwide population-based cohort study. J. Evid. Based Med. 17, 296\u2013306 (2024).","journal-title":"J. Evid. Based Med."},{"key":"918_CR143","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1210\/clinem\/dgae352","volume":"109","author":"F Geurts","year":"2024","unstructured":"Geurts, F. et al. The effect of thiazide diuretics on urinary prostaglandin E2 excretion and serum sodium in the general population. J. Clin. Endocrinol. Metab. 109, 2444\u20132451 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"918_CR144","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/bmj.285.6335.89","volume":"285","author":"G Decaux","year":"1982","unstructured":"Decaux, G., Waterlot, Y., Genette, F., Hallemans, R. & Demanet, J. C. Inappropriate secretion of antidiuretic hormone treated with frusemide. Br. Med. J. 285, 89\u201390 (1982).","journal-title":"Br. Med. J."},{"key":"918_CR145","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.ajkd.2019.11.012","volume":"76","author":"P Krisanapan","year":"2020","unstructured":"Krisanapan, P., Vongsanim, S., Pin-On, P., Ruengorn, C. & Noppakun, K. Efficacy of furosemide, oral sodium chloride, and fluid restriction for treatment of syndrome of inappropriate antidiuresis (SIAD): an open-label randomized controlled study (The EFFUSE-FLUID Trial). Am. J. Kidney Dis. 76, 203\u2013212 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"918_CR146","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1681\/ASN.2022050623","volume":"34","author":"J Refardt","year":"2023","unstructured":"Refardt, J. et al. Treatment effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial. J. Am. Soc. Nephrol. 34, 322\u2013332 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"918_CR147","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM197010152831603","volume":"283","author":"WN Suki","year":"1970","unstructured":"Suki, W. N. et al. Acute treatment of hypercalcemia with furosemide. N. Engl. J. Med. 283, 836\u2013840 (1970).","journal-title":"N. Engl. J. Med."},{"key":"918_CR148","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ecl.2021.08.002","volume":"50","author":"M Chakhtoura","year":"2021","unstructured":"Chakhtoura, M. & El-Hajj Fuleihan, G. Treatment of hypercalcemia of malignancy. Endocrinol. Metab. Clin. North. Am. 50, 781\u2013792 (2021).","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"918_CR149","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","volume":"149","author":"SB LeGrand","year":"2008","unstructured":"LeGrand, S. B., Leskuski, D. & Zama, I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann. Intern. Med. 149, 259\u2013263 (2008).","journal-title":"Ann. Intern. Med."},{"key":"918_CR150","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7326\/0003-4819-150-2-200901200-00020","volume":"150","author":"RB Robey","year":"2009","unstructured":"Robey, R. B., Lash, J. P. & Arruda, J. A. Does furosemide have a role in the management of hypercalcemia? Ann. Intern. Med. 150, 146\u2013147 (2009). author reply 147.","journal-title":"Ann. Intern. Med."},{"key":"918_CR151","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1681\/ASN.2007111194","volume":"20","author":"KJ Martin","year":"2009","unstructured":"Martin, K. J., Gonzalez, E. A. & Slatopolsky, E. Clinical consequences and management of hypomagnesemia. J. Am. Soc. Nephrol. 20, 2291\u20132295 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"918_CR152","first-page":"274","volume":"3","author":"MP Ryan","year":"1984","unstructured":"Ryan, M. P. Magnesium- and potassium-sparing effects of amiloride. Review and recent findings. Magnesium 3, 274\u2013288 (1984).","journal-title":"Magnesium"},{"key":"918_CR153","first-page":"259","volume":"28","author":"O Wrong","year":"1959","unstructured":"Wrong, O. & Davies, H. E. The excretion of acid in renal disease. Q. J. Med. 28, 259\u2013313 (1959).","journal-title":"Q. J. Med."},{"key":"918_CR154","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.ki.5002220","volume":"71","author":"SB Walsh","year":"2007","unstructured":"Walsh, S. B., Shirley, D. G., Wrong, O. M. & Unwin, R. J. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. Kidney Int. 71, 1310\u20131316 (2007).","journal-title":"Kidney Int."},{"key":"918_CR155","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2215\/CJN.01320217","volume":"12","author":"NA Dhayat","year":"2017","unstructured":"Dhayat, N. A. et al. Furosemide\/fludrocortisone test and clinical parameters to diagnose incomplete distal renal tubular acidosis in kidney stone formers. Clin. J. Am. Soc. Nephrol. 12, 1507\u20131517 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"918_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/cc13015","volume":"17","author":"LS Chawla","year":"2013","unstructured":"Chawla, L. S. et al. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit. Care 17, R207 (2013).","journal-title":"Crit. Care"},{"key":"918_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02912-8","volume":"24","author":"JJ Chen","year":"2020","unstructured":"Chen, J. J., Chang, C. H., Huang, Y. T. & Kuo, G. Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis. Crit. Care 24, 202 (2020).","journal-title":"Crit. Care"},{"key":"918_CR158","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/HYPERTENSIONAHA.114.03946","volume":"64","author":"P Klemmer","year":"2014","unstructured":"Klemmer, P., Grim, C. E. & Luft, F. C. Who and what drove Walter Kempner? The rice diet revisited. Hypertension 64, 684\u2013688 (2014).","journal-title":"Hypertension"},{"key":"918_CR159","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott, W. J. & Meyer, P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369, 201\u2013207 (2007).","journal-title":"Lancet"},{"key":"918_CR160","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1161\/CIRCULATIONAHA.107.695007","volume":"117","author":"FH Messerli","year":"2008","unstructured":"Messerli, F. H., Bangalore, S. & Julius, S. Risk\/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117, 2706\u20132715 (2008). discussion 2715.","journal-title":"Circulation"},{"key":"918_CR161","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/bmj.309.6949.226","volume":"309","author":"R Harper","year":"1994","unstructured":"Harper, R. et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 309, 226\u2013230 (1994).","journal-title":"BMJ"},{"key":"918_CR162","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0002-8703(00)90325-9","volume":"139","author":"MR Weir","year":"2000","unstructured":"Weir, M. R. & Moser, M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am. Heart J. 139, 174\u2013183 (2000).","journal-title":"Am. Heart J."},{"key":"918_CR163","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.3390\/cancers14102566","volume":"14","author":"S Nochaiwong","year":"2022","unstructured":"Nochaiwong, S. et al. Use of thiazide diuretics and risk of all types of skin cancers: an updated systematic review and meta-analysis. Cancers 14, 2566 (2022).","journal-title":"Cancers"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00918-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00918-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00918-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T22:17:27Z","timestamp":1742595447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-024-00918-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":163,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1038\/s41581-024-00918-x","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A. served as a member of the executive steering committees of the FIDELIO and FIGARO trials, continues to serve on the steering committee of the FIND-CKD and CONFIDENCE trials and as the principal investigator for CONFIDENCE; all of these trials are funded by Bayer. R.A. serves as a consultant for Bayer, Covance, and Boehringer Ingelheim; served on the executive steering committees for Akebia for their HIF-PHI trials and as a consultant; chairs adjudication committees for Alnylam and Intercept Pharma and Data safety monitoring boards for Chinook, Vertex, and Eloxx. R.A. receives royalties from UpToDate and serves as Associate Editor of the American Journal of Nephrology and Nephrology Dialysis and Transplantation. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}